Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction
- PMID: 14502221
- DOI: 10.1038/sj.gt.3302093
Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction
Abstract
Autologous transplantation of gene-modified hematopoietic stem cells may provide a therapeutic strategy for several monogeneic disorders. In previous studies, retroviral gene transfer of coagulation factor VIII (FVIII) into FVIII(-/-) mouse bone marrow (BM) cells did not result in detectable plasma FVIII levels. However, specific immune tolerance was achieved against neo-antigenic FVIII. Here, we used lentiviral vectors to study the ability of various hematopoietic cell types to synthesize and secrete recombinant FVIII. Several myeloid, monocytic and megakaryocytic cell lines (K-562, TF-1, Monomac-1, Mutz-3, Meg-01) expressed FVIII at 2-12 mU/10(4) cells. In contrast, two lymphatic cell lines, BV-173 and Molt-4, were less-efficiently transduced and did not express detectable FVIII. Similarly, peripheral blood-derived primary monocytes were transduced efficiently and expressed up to 20 mU/10(4) cells, whereas primary lymphocytes did not express FVIII. Although human and canine CD34(+) cells were transduced efficiently, the cells expressed very low levels of FVIII (up to 0.8 mU/10(4) cells). Following xenotransplantation of transduced CD34(+) into NOD/SCID mice, ELISA failed to detect FVIII in the plasma of engrafted mice. However, NOD/SCID repopulating cell (SRC)-derived human monocytes isolated from BM of these mice secreted functional recombinant FVIII after culture ex vivo. Again, SRC-derived human lymphocytes did not secrete FVIII. Therefore, certain hematopoietic cell types are able to synthesize and secrete functional recombinant FVIII. Our results show for the first time that transplantation of transduced CD34(+) progenitors may give rise to differentiated hematopoietic cells secreting a nonhematopoietic recombinant protein.
Similar articles
-
Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice.J Gene Med. 2004 Oct;6(10):1049-60. doi: 10.1002/jgm.609. J Gene Med. 2004. PMID: 15386735
-
Transduction of human CD34+ CD38- bone marrow and cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors.Mol Ther. 2000 Jun;1(6):566-73. doi: 10.1006/mthe.2000.0077. Mol Ther. 2000. PMID: 10933981
-
High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector.Stem Cells. 2001;19(3):247-59. doi: 10.1634/stemcells.19-3-247. Stem Cells. 2001. PMID: 11359950
-
Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies.Semin Thromb Hemost. 2004 Apr;30(2):185-95. doi: 10.1055/s-2004-825632. Semin Thromb Hemost. 2004. PMID: 15118930 Review.
-
Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator.Ann N Y Acad Sci. 2005;1054:238-49. doi: 10.1196/annals.1345.030. Ann N Y Acad Sci. 2005. PMID: 16339671 Review.
Cited by
-
Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.Blood. 2008 Oct 1;112(7):2713-21. doi: 10.1182/blood-2008-02-138214. Epub 2008 May 21. Blood. 2008. PMID: 18495954 Free PMC article.
-
A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.Mol Ther. 2011 Apr;19(4):723-30. doi: 10.1038/mt.2010.290. Epub 2011 Feb 1. Mol Ther. 2011. PMID: 21285959 Free PMC article.
-
Factor VIII ectopically _targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.J Clin Invest. 2006 Jul;116(7):1974-82. doi: 10.1172/JCI28416. J Clin Invest. 2006. PMID: 16823491 Free PMC article.
-
In vivo efficacy of platelet-delivered, high specific activity factor VIII variants.Blood. 2010 Dec 23;116(26):6114-22. doi: 10.1182/blood-2010-06-293308. Epub 2010 Sep 17. Blood. 2010. PMID: 20852129 Free PMC article.
-
Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens.Blood. 2007 Oct 15;110(8):2855-63. doi: 10.1182/blood-2007-04-082602. Epub 2007 Jun 14. Blood. 2007. PMID: 17569821 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous